Comparison of the efficacy of betaxolol-brinzolamide and timolol- dorzolamide as suppressors of aqueous humor flow in human subjects

Ophthalmology

Volumn 107, Issue 2, 2000, Pages 283-287

  Brubaker, Richard F ^a   Ingram, Cory J ^a   Schoff, Erik O ^a   Nau, Cherie B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL; BRINZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL;

ADULT; AGED; AQUEOUS HUMOR FLOW; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; ENZYME INHIBITION; FEMALE; FLUOROPHOTOMETRY; HUMAN; HYPOTENSION; INTRAOCULAR PRESSURE; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AQUEOUS HUMOR; BETAXOLOL; CARBONIC ANHYDRASE INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROPHOTOMETRY; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; SAFETY; SULFONAMIDES; THIAZINES; THIOPHENES; TIMOLOL; TONOMETRY, OCULAR;

EID: 0034029713     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)00044-5     Document Type: Article

References (24)

1. Wayman L., Larsson L.I., Maus T., et al. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 115:1997;1368-1371.
2. Wayman L.L., Larsson L.I., Maus T.L., Brubaker R.F. Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol. Arch Ophthalmol. 116:1998;1438-1440.
3. Clineschmidt C.M., Williams R.D., Snyder E., Adamsons I.A. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. The Dorzolamide-Timolol Combination Study Group. Ophthalmology. 105:1998;1952-1959.
4. Schlecht L.P., Brubaker R.F. The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmology. 95:1988;1212-1216.
5. Wilkerson M., Cyrlin M., Lippa E.A., et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol. 111:1993;1343-1350.
6. Ingram C.J., Brubaker R.F. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 128:1999;292-296.
7. Silver L.H. Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. The Clinical Brinzolamide Primary Therapy Study Group. Am J Ophthalmol. 126:1998;400-408.
8. Coakes R.L., Brubaker R.F. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch Ophthalmol. 96:1978;2045-2048.
9. Yablonski M.E., Zimmerman T.J., Waltman S.R., Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 27:1978;135-142.
10. Coulangeon L.M., Sole M., Menerath J.M., Sole P. Débit de l'humeur aqueuse mesuré par fluorophotométrie. Etude comparative de l'effet de differents collyres bêta-bloquants chez des patients ayant une hypertonie oculaire. [Eng. abstr.] Ophtalmologie. 4:1990;156-161.
11. Alm A., Koskela T., Taarnhøj J. Effects of D-timolol and L-timolol eye drops on intraocular pressure and aqueous flow a dose-response study in normal eyes . Acta Ophthalmol (Copenh). 68:1990;19-22.
12. Coulangeon L.M., Menerath J.M., Sole P., Plane C. Fluorophotométrie par instillation. II. Effet d'un collyre bêta-bloquant chez le sujet normal. [Eng. abstr] J Fr Opthalmol. 10:1987;375-380.
13. Brubaker R.F., Nagataki S., Bourne W.M. Effect of chronically administered timolol on aqueous humor flow in patients with glaucoma. Ophthalmology. 89:1982;280-283.
14. Dailey R.A., Brubaker R.F., Bourne W.M. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol. 93:1982;232-237.
15. Stepanik J. Timolol versus Diamox. [Eng. abstr.] Klin Monatsbl Augenheilled. 179:1981;280-282.
16. Schenker H.I., Yablonski M.E., Podos S.M., Linder L. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol. 99:1981;1212-1216.
17. Larsson L.I., Alm A. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide. Arch Ophthalmol. 116:1998;19-24.
18. Yamazaki Y., Miyamoto S., Sawa M. Effect of MK-507 on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 38:1994;92-96.
19. Strahlman E., Tipping R., Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. The International Dorzolamide Study Group. Arch Ophthalmol. 113:1995;1009-1016.
20. Schadlu R., Maus T.L., Nau C.B., Brubaker R.F. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol. 116:1998;1441-1444.
21. Maus T.L., Larsson L.I., McLaren J.W., Brubaker R.F. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 115:1997;45-49.
22. Jones R.F., Maurice D.M. New methods of measuring the rate of aqueous flow in man with fluorescein. Exp Eye Res. 5:1966;208-220.
23. Brubaker R.F. Measurement of aqueous flow by fluorophotometry. Ritch R., Shields M.B., Krupin T. The Glaucomas. ed. 2 :1996;447-454 Mosby, St. Louis.
24. Maus T.L., Nau C., Brubaker R.F. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 117:1999;586-591.